Zanoterone
![]() | |
Identifiers | |
---|---|
107000-34-0 | |
ChemSpider | 8020541 |
Jmol interactive 3D | Image |
PubChem | 9844827 |
| |
| |
Properties | |
C23H32N2O3S | |
Molar mass | 416.58 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Infobox references | |
Zanoterone (INN, USAN) (former developmental codename WIN-49596) is a steroidal antiandrogen.[1][2] It was investigated for the treatment of benign prostatic hyperplasia (BPH) but failed to demonstrate sufficient efficacy in phase II clinical trials, and also showed an unacceptable incidence rate and severity of side effects (e.g., gynecomastia).[3][4] As such, it was not further developed, and hence was never marketed.[3][4]
See also
References
- ↑ Dr. Ian Morton; I.K. Morton; Judith M. Hall (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 294–. ISBN 978-0-7514-0499-9.
- ↑ C.R. Ganellin; David J. Triggle (1997). Dictionary of Pharmacological Agents. Taylor & Francis. pp. 540–. ISBN 978-0-412-46630-4.
- 1 2 Virgil Craig Jordan; B. J. A. Furr (5 February 2010). Hormone Therapy in Breast and Prostate Cancer. Springer Science & Business Media. pp. 328–. ISBN 978-1-59259-152-7.
- 1 2 Alan J. Wein; Louis R. Kavoussi; Andrew C. Novick; Alan W. Partin; Craig A. Peters (28 September 2011). Campbell-Walsh Urology. Elsevier Health Sciences. pp. 2637–. ISBN 1-4557-2298-7.
|
This article is issued from Wikipedia - version of the Monday, July 20, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.